{"id":282092,"date":"2026-10-01T09:34:19","date_gmt":"2026-10-01T04:04:19","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=282092"},"modified":"2026-10-01T09:34:19","modified_gmt":"2026-10-01T04:04:19","slug":"aurobindo-pharma-share-price-adquey-launch","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/","title":{"rendered":"Aurobindo&#8217;s US Arm Launches ADQUEY Ointment, Marking Its Entry Into the Dermatology Market"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Aurobindo Pharma Rs 1,677.90, up 0.35% (1 Oct, 9:13 AM). Acrotech Biopharma launches ADQUEY (difamilast 1%) ointment in US for atopic dermatitis, ages 2+. P\/E 25.84 vs industry 38.34.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Aurobindo Pharma share price was Rs 1,677.90 at 9:13 AM on 1 October 2026, up 0.35 percent, after the company&#8217;s biopharmaceutical subsidiary Acrotech Biopharma announced the US launch of ADQUEY, a difamilast 1 percent ointment. ADQUEY is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and older. The launch marks Acrotech&#8217;s entry into the US dermatology market, expanding the subsidiary&#8217;s portfolio beyond its existing oncology and hematology focus. Aurobindo Pharma trades at a P\/E of 25.84 against a pharmaceutical industry average of 38.34, a discount that reflects the company&#8217;s largely generic-drug revenue base.<\/p>\n<\/div>\n<p>Aurobindo Pharma Limited said its biopharmaceutical subsidiary Acrotech Biopharma Inc. has announced the US launch of ADQUEY, a difamilast 1 percent ointment. ADQUEY is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and older, and the launch marks Acrotech&#8217;s entry into the US dermatology market.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=aurobindo-pharma-share-price-adquey-launch\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>The announcement did not include pricing, projected revenue contribution or launch volume figures. This article covers what the product addresses, the stock&#8217;s current levels, and the risks for investors.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#What_ADQUEY_Is_and_What_It_Means_for_Aurobindo\" title=\"What ADQUEY Is and What It Means for Aurobindo\">What ADQUEY Is and What It Means for Aurobindo<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Aurobindo_Pharma_Share_Price_Today_Numbers_and_Technical_Levels\" title=\"Aurobindo Pharma Share Price Today: Numbers and Technical Levels\">Aurobindo Pharma Share Price Today: Numbers and Technical Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Valuation_Behind_the_Aurobindo_Pharma_Share_Price\" title=\"Valuation Behind the Aurobindo Pharma Share Price\">Valuation Behind the Aurobindo Pharma Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Risks_for_the_Aurobindo_Pharma_Share_Price\" title=\"Risks for the Aurobindo Pharma Share Price\">Risks for the Aurobindo Pharma Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#What_is_the_Aurobindo_Pharma_share_price_today\" title=\"What is the Aurobindo Pharma share price today?\">What is the Aurobindo Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#What_product_has_Aurobindos_subsidiary_launched\" title=\"What product has Aurobindo&#8217;s subsidiary launched?\">What product has Aurobindo&#8217;s subsidiary launched?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#What_is_Acrotech_Biopharmas_usual_therapeutic_focus\" title=\"What is Acrotech Biopharma&#8217;s usual therapeutic focus?\">What is Acrotech Biopharma&#8217;s usual therapeutic focus?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Is_ADQUEY_a_steroid-based_treatment\" title=\"Is ADQUEY a steroid-based treatment?\">Is ADQUEY a steroid-based treatment?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Is_the_Aurobindo_Pharma_share_price_expensive\" title=\"Is the Aurobindo Pharma share price expensive?\">Is the Aurobindo Pharma share price expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#What_are_the_key_technical_levels_for_the_Aurobindo_Pharma_share_price\" title=\"What are the key technical levels for the Aurobindo Pharma share price?\">What are the key technical levels for the Aurobindo Pharma share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#How_far_is_Aurobindo_Pharma_from_its_52-week_high\" title=\"How far is Aurobindo Pharma from its 52-week high?\">How far is Aurobindo Pharma from its 52-week high?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-share-price-adquey-launch\/#Should_I_buy_Aurobindo_Pharma_shares_after_this_launch\" title=\"Should I buy Aurobindo Pharma shares after this launch?\">Should I buy Aurobindo Pharma shares after this launch?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_ADQUEY_Is_and_What_It_Means_for_Aurobindo\"><\/span><strong>What ADQUEY Is and What It Means for Aurobindo<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellpadding=\"6\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;\">Item<\/th>\n<th style=\"text-align:left;\">Detail<\/th>\n<\/tr>\n<tr>\n<td>Launching entity<\/td>\n<td>Acrotech Biopharma Inc. (Aurobindo Pharma subsidiary)<\/td>\n<\/tr>\n<tr>\n<td>Product<\/td>\n<td>ADQUEY (difamilast 1%) ointment<\/td>\n<\/tr>\n<tr>\n<td>Indication<\/td>\n<td>Mild-to-moderate atopic dermatitis<\/td>\n<\/tr>\n<tr>\n<td>Eligible patients<\/td>\n<td>Adults and pediatric patients aged 2 years and older<\/td>\n<\/tr>\n<tr>\n<td>Classification<\/td>\n<td>Non-steroidal topical treatment<\/td>\n<\/tr>\n<tr>\n<td>Significance<\/td>\n<td>Marks Acrotech&#8217;s entry into the US dermatology market<\/td>\n<\/tr>\n<\/table>\n<p>Acrotech Biopharma has historically focused on oncology and hematology products, so a dermatology launch represents a diversification of its therapeutic focus within the US market. Non-steroidal topical treatments for atopic dermatitis are a growing category, as patients and physicians often seek alternatives to long-term steroid-based creams for chronic skin conditions.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/stocks-to-watch-today-01102026\">Stocks to Watch Today: Alicon Castalloy Jumps 20%, Ircon and Rites Surge on Heavy Volume<\/a><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Aurobindo_Pharma_Share_Price_Today_Numbers_and_Technical_Levels\"><\/span><strong>Aurobindo Pharma Share Price Today: Numbers and Technical Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellpadding=\"6\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;\">Metric<\/th>\n<th style=\"text-align:left;\">Value (1 Oct, 9:13 AM)<\/th>\n<\/tr>\n<tr>\n<td>Aurobindo Pharma share price<\/td>\n<td>Rs 1,677.90 (up 0.35%)<\/td>\n<\/tr>\n<tr>\n<td>Previous close<\/td>\n<td>Rs 1,672.00<\/td>\n<\/tr>\n<tr>\n<td>52-week high \/ low<\/td>\n<td>Rs 1,740.00 \/ Rs 1,066.80<\/td>\n<\/tr>\n<tr>\n<td>RSI (14-day)<\/td>\n<td>51.9<\/td>\n<\/tr>\n<tr>\n<td>SuperTrend<\/td>\n<td>Bullish, support at Rs 1,607.04<\/td>\n<\/tr>\n<tr>\n<td>20-day average<\/td>\n<td>Rs 1,686.23<\/td>\n<\/tr>\n<tr>\n<td>Market cap<\/td>\n<td>Rs 95,887 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E vs industry P\/E<\/td>\n<td>25.84 vs 38.34<\/td>\n<\/tr>\n<tr>\n<td>Return on equity<\/td>\n<td>9.25%<\/td>\n<\/tr>\n<\/table>\n<p>The Aurobindo Pharma share price is just 3.6 percent below its 52-week high of Rs 1,740, trading close to its 20-day average of Rs 1,686.23 with a neutral RSI of 51.9. The SuperTrend indicator remains bullish with support at Rs 1,607.04.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Pharma Stocks and Live Levels on the Univest Screener<\/strong><\/a><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Valuation_Behind_the_Aurobindo_Pharma_Share_Price\"><\/span><strong>Valuation Behind the Aurobindo Pharma Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Aurobindo Pharma trades at a P\/E of 25.84 against a pharmaceutical industry average of 38.34, a discount that reflects the company&#8217;s revenue base, which is still largely weighted toward generic drugs rather than the specialty and branded products that typically command higher multiples. Return on equity of 9.25 percent and debt to equity of 0.21 are moderate.<\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Risks_for_the_Aurobindo_Pharma_Share_Price\"><\/span><strong>Risks for the Aurobindo Pharma Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>New product launches like ADQUEY typically take time to build meaningful revenue, so the near-term financial impact on Aurobindo&#8217;s consolidated results is likely to be limited. Competitive intensity in the US dermatology and topical treatment market, where several established players already operate, is a factor for Acrotech&#8217;s new entry. US regulatory and pricing risk for pharmaceutical products generally, including scrutiny of drug pricing, remains a structural consideration for the sector.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Aurobindo Pharma share price and get alerts on new product launches.<\/em><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Aurobindo Pharma share price edged higher after US subsidiary Acrotech Biopharma launched ADQUEY ointment, marking its entry into the dermatology market, though the near-term financial contribution is likely to be limited. A valuation discount to the pharma industry average and a bullish technical trend are supports, while competitive intensity in US dermatology and typical new-launch ramp-up time are the considerations. Investors deciding whether to buy Aurobindo Pharma shares should watch the Rs 1,686.23 average as resistance, follow stop-loss levels and consult a SEBI-registered adviser.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_is_the_Aurobindo_Pharma_share_price_today\"><\/span><strong>What is the Aurobindo Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Aurobindo Pharma share price was Rs 1,677.90 at 9:13 AM on 1 October 2026, up 0.35 percent from Rs 1,672.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_product_has_Aurobindos_subsidiary_launched\"><\/span><strong>What product has Aurobindo&#8217;s subsidiary launched?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Acrotech Biopharma launched ADQUEY, a difamilast 1 percent ointment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two and older.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_is_Acrotech_Biopharmas_usual_therapeutic_focus\"><\/span><strong>What is Acrotech Biopharma&#8217;s usual therapeutic focus?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It has historically focused on oncology and hematology products, so this dermatology launch is a diversification into a new therapeutic area.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Is_ADQUEY_a_steroid-based_treatment\"><\/span><strong>Is ADQUEY a steroid-based treatment?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. It is described as a non-steroidal topical treatment for atopic dermatitis.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Is_the_Aurobindo_Pharma_share_price_expensive\"><\/span><strong>Is the Aurobindo Pharma share price expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The P\/E of 25.84 is below the pharmaceutical industry average of 38.34, a discount tied to the company&#8217;s largely generic-drug revenue base.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_are_the_key_technical_levels_for_the_Aurobindo_Pharma_share_price\"><\/span><strong>What are the key technical levels for the Aurobindo Pharma share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key levels are SuperTrend support at Rs 1,607.04 and the 20-day average of Rs 1,686.23. The RSI is 51.9.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"How_far_is_Aurobindo_Pharma_from_its_52-week_high\"><\/span><strong>How far is Aurobindo Pharma from its 52-week high?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock is about 3.6 percent below its 52-week high of Rs 1,740.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Should_I_buy_Aurobindo_Pharma_shares_after_this_launch\"><\/span><strong>Should I buy Aurobindo Pharma shares after this launch?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The launch is a long-term positive for diversification, but near-term revenue impact is likely limited. Use a stop-loss and consult a SEBI-registered adviser.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Aurobindo Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Aurobindo Pharma share price was Rs 1,677.90 at 9:13 AM on 1 October 2026, up 0.35 percent from Rs 1,672.\"}},{\"@type\":\"Question\",\"name\":\"What product has Aurobindo's subsidiary launched?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Acrotech Biopharma launched ADQUEY, a difamilast 1 percent ointment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two and older.\"}},{\"@type\":\"Question\",\"name\":\"What is Acrotech Biopharma's usual therapeutic focus?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It has historically focused on oncology and hematology products, so this dermatology launch is a diversification into a new therapeutic area.\"}},{\"@type\":\"Question\",\"name\":\"Is ADQUEY a steroid-based treatment?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. It is described as a non-steroidal topical treatment for atopic dermatitis.\"}},{\"@type\":\"Question\",\"name\":\"Is the Aurobindo Pharma share price expensive?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of 25.84 is below the pharmaceutical industry average of 38.34, a discount tied to the company's largely generic-drug revenue base.\"}},{\"@type\":\"Question\",\"name\":\"What are the key technical levels for the Aurobindo Pharma share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The key levels are SuperTrend support at Rs 1,607.04 and the 20-day average of Rs 1,686.23. The RSI is 51.9.\"}},{\"@type\":\"Question\",\"name\":\"How far is Aurobindo Pharma from its 52-week high?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The stock is about 3.6 percent below its 52-week high of Rs 1,740.\"}},{\"@type\":\"Question\",\"name\":\"Should I buy Aurobindo Pharma shares after this launch?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The launch is a long-term positive for diversification, but near-term revenue impact is likely limited. Use a stop-loss and consult a SEBI-registered adviser.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Aurobindo&#8217;s US arm launched ADQUEY ointment, entering the dermatology market. Here is what the product does, the levels and the risks.<\/p>\n","protected":false},"author":28,"featured_media":282089,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[1007,1019],"class_list":["post-282092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-pharma-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["282089"],"rank_math_title":["Aurobindo Pharma Share Price: ADQUEY US Launch"],"rank_math_description":["Aurobindo Pharma share price is Rs 1,677.90, up 0.35%, after US arm Acrotech Biopharma launched ADQUEY ointment, entering the dermatology market. Levels and risks."],"rank_math_focus_keyword":["Aurobindo Pharma share price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/aurobindo-s-us-arm-launches-adquey-ointment-marking-its-entry-into-the.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/282092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=282092"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/282092\/revisions"}],"predecessor-version":[{"id":282095,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/282092\/revisions\/282095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/282089"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=282092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=282092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=282092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}